Advanced Enzyme FY26 profit up 30% with FY27 plans

What the company reported

Advanced Enzyme Technologies has announced its audited results for the quarter and year ended March 31, 2026, showing higher profitability and steady margin performance. Consolidated net profit for FY26 rose 30% year-on-year to ₹173.61 crore, while revenue from operations increased 17% to ₹745.76 crore. For Q4 FY26, the company reported revenue from operations of ₹203.37 crore, up 22% year-on-year, and net profit of ₹45.25 crore, up 69%. EBITDA for Q4 FY26 rose to ₹63.20 crore from ₹45.60 crore, with the EBITDA margin improving to 31% from 27%. For the full year, consolidated EBITDA was ₹229.10 crore versus ₹194.40 crore, while the EBITDA margin remained at 31%. The company said the results reflect broad-based growth across all four business segments.

Board decisions: dividend, ESOP allotment, and capital stance

The Board of Directors met on May 09, 2026 to approve audited annual financial results (standalone and consolidated) along with Q4 FY26 results. The board recommended a final dividend of ₹1.35 per equity share for FY26, subject to shareholder approval at the ensuing 37th Annual General Meeting. The company also noted the dividend represents 67.5% on the face value of ₹2 per share. Separately, the board decided to defer the declaration of an interim dividend, citing the need to preserve capital flexibility while evaluating potential strategic avenues and corporate actions. The company also allotted 49,350 equity shares under its ESOP Scheme 2022 and approved director reappointments.

Consolidated performance: Q4 and FY26 in numbers

In Q4 FY26, profit before tax rose to ₹59.80 crore from ₹43.46 crore, while net profit increased to ₹45.25 crore from ₹26.73 crore. For FY26, profit before tax stood at ₹232.54 crore compared with ₹187.36 crore in FY25, and net profit rose to ₹173.61 crore from ₹133.97 crore. The company also disclosed total comprehensive income of ₹268.42 crore for FY26 versus ₹152.80 crore in FY25. Basic EPS for FY26 was ₹15.08, compared with ₹11.72 in FY25, while Q4 FY26 basic EPS was ₹3.84 versus ₹2.37 in Q4 FY25. Financial costs declined to ₹0.60 crore in Q4 FY26 from ₹0.80 crore in Q4 FY25.

Segment performance: Human Nutrition led growth

The Human Nutrition segment remained the largest contributor, accounting for 63% of total revenue in Q4 FY26. Segment revenue rose 24% year-on-year to ₹128.10 crore in Q4 FY26, driven by increased activities in the Pharma/API and Bio-catalysis businesses. For FY26, Human Nutrition revenue grew 15% to ₹467.40 crore. Animal Nutrition revenue increased 19% to ₹25.00 crore in Q4 FY26 and grew 25% to ₹94.60 crore for FY26. Bio-Processing reported 17% growth in Q4 FY26 to ₹32.40 crore, while Specialized Manufacturing rose 17% to ₹18.00 crore.

Geography and sales mix: India drives Q4, mixed overseas trends

India was the largest market in Q4 FY26, contributing 52% of revenue at ₹106.10 crore, a 51% year-on-year increase. Domestic sales accounted for 50% of total revenue for FY26. International sales were ₹97.30 crore in Q4 FY26, and the company noted that the Americas and Europe saw declines of 11% and 7% respectively. Asia (excluding India) grew 38% during the quarter, as per the company’s geographic update. The mix indicates that the quarter’s growth was supported primarily by domestic traction, while overseas performance varied by region.

Standalone results and balance sheet highlights

On a standalone basis, revenue from operations rose to ₹452.77 crore in FY26 from ₹351.41 crore in FY25. Standalone net profit increased to ₹131.81 crore from ₹102.42 crore. On the balance sheet, consolidated total assets stood at ₹1,838.76 crore as at March 31, 2026, compared with ₹1,621.35 crore as at March 31, 2025. Consolidated total equity increased to ₹1,683.12 crore from ₹1,468.67 crore. Standalone total assets were ₹803.64 crore versus ₹688.63 crore, with total equity rising to ₹709.62 crore from ₹629.34 crore.

Exceptional items and audit position

The company disclosed exceptional items in FY26 consolidated results amounting to a net credit of ₹11.36 crore. This included a reversal of a provision of ₹15.96 crore related to a lawsuit against Advanced Supplementary Technologies Corporation (U.S.A.) after a favourable direction by the United States Court of Appeals, partially offset by an additional foreign exchange impact of ₹0.18 crore in Q4 FY26. The company also recognised an incremental impact of ₹4.63 crore (gratuity) and ₹0.15 crore (compensated absences) under exceptional items, linked to the Government of India’s notification of four Labour Codes on November 21, 2025. On a standalone basis, an exceptional item of ₹3.86 crore was recognised due to the Labour Code changes. The statutory auditors, M S K A & Associates LLP, issued an unmodified audit opinion on both standalone and consolidated financial results for FY26.

FY27 strategy: Wellfa B2C expansion and wider sales reach

Alongside the results, the company outlined its FY27 plans with an emphasis on B2C expansion and geographic diversification. It plans to expand its Wellfa nutraceutical B2C brand in India. In Animal Nutrition, it plans to grow sales teams across the USA, MENA, and Asian regions. The company positioned these steps as part of its broader effort to build scale in targeted end-markets and strengthen go-to-market coverage.

Compliance update and upcoming investor call

Advanced Enzyme Technologies also submitted its mandatory SEBI compliance certificate for Q4 FY26 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations. Separately, it announced a conference call for analysts and investors to discuss the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST, with primary dial-in numbers +91 86 3416 8438 and +91 86 4536 6489 and a participant PIN (International) 4773312#. The company’s investor relations contact for RSVP was shared as ir@advancedenzymes.com.

Why the results matter

The FY26 print shows Advanced Enzyme lifting profit growth faster than revenue, supported by Q4 margin expansion to 31% EBITDA margin and higher quarterly profitability. Domestic growth stood out, with India revenue rising 51% year-on-year in Q4 FY26 and accounting for 52% of quarterly revenue, while international performance was mixed across regions. The FY27 plan highlights two operational priorities visible in the disclosures: building a consumer-facing nutraceutical presence through Wellfa in India and strengthening Animal Nutrition coverage through added sales capacity across multiple regions. The next formal update for investors is expected through the scheduled May 12, 2026 conference call.